{"id":"NCT01763918","sponsor":"Amgen","briefTitle":"Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2","officialTitle":"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02-07","primaryCompletion":"2013-11-27","completion":"2013-12-19","firstPosted":"2013-01-09","resultsPosted":"2015-12-22","lastUpdate":"2019-06-17"},"enrollment":331,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperlipidemia"],"interventions":[{"type":"BIOLOGICAL","name":"Evolocumab","otherNames":["AMG 145","Repatha"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"Placebo QM","type":"PLACEBO_COMPARATOR"},{"label":"Evolocumab Q2W","type":"EXPERIMENTAL"},{"label":"Evolocumab QM","type":"EXPERIMENTAL"}],"summary":"The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolemia (HeFH).","primaryOutcome":{"measure":"Percent Change From Baseline in LDL-C at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo Q2W","deltaMin":-2.02,"sd":2.49},{"arm":"Placebo QM","deltaMin":5.53,"sd":3.25},{"arm":"Evolocumab Q2W","deltaMin":-61.25,"sd":1.77},{"arm":"Evolocumab QM","deltaMin":-55.74,"sd":2.25}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":39,"countries":["United States","Australia","Canada","France","Germany","Hong Kong","Netherlands","New Zealand","Norway","South Africa","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["28249876","29736889","29353350","29768954","25282519","30755061","30120772"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":54},"commonTop":["Nasopharyngitis","Headache","Arthralgia","Back pain","Dizziness"]}}